Achieve Life Sciences (ACHV) Depreciation & Amortization (CF) (2010 - 2026)
Achieve Life Sciences (ACHV) recorded quarterly Depreciation & Amortization (CF) of $57000.0 in Q1 2026, little changed on a QoQ basis from $57000.0 in Q4 2025, and down 8.06% year-over-year from $62000.0 in Q1 2025.
Achieve Life Sciences (ACHV) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Achieve Life Sciences has disclosed Depreciation & Amortization (CF) across 17 years of filings, most recently posting $57000.0 for Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 8.06% year-over-year to $57000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $223000.0 (down 4.7% YoY) and the FY2025 annual result came in at $228000.0, changed 0.44% from the prior year.
- Depreciation & Amortization (CF) held at $57000.0 in Q1 2026, from $57000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $65000.0 in Q4 2022 and troughed at $54000.0 in Q3 2025.
- A 5-year average of $57529.4 and a median of $57000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) retreated 12.31% — and 2025, when it rose 8.77%.
- Tracing ACHV's Depreciation & Amortization (CF) over 5 years: stood at $65000.0 in 2022, then fell by 12.31% to $57000.0 in 2023, then grew by 1.75% to $58000.0 in 2024, then retreated by 1.72% to $57000.0 in 2025, then changed by 0.0% to $57000.0 in 2026.
- Business Quant data shows ACHV's Depreciation & Amortization (CF) at $57000.0 in Q1 2026, $57000.0 in Q4 2025, and $54000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 1,395.22 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 429,663.65 |
| 10 | Achieve Life Sciences | 93.71 Mn | 63.22 Mn | - | 57,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 57,000.00 |
| Mar 31, 2026 | 57,000.00 |
| Dec 31, 2025 | 57,000.00 |
| Dec 31, 2025 | 57,000.00 |
| Sep 30, 2025 | 54,000.00 |
| Sep 30, 2025 | 54,000.00 |
| Jun 30, 2025 | 55,000.00 |
| Jun 30, 2025 | 55,000.00 |
| Mar 31, 2025 | 62,000.00 |
| Mar 31, 2025 | 62,000.00 |
| Dec 31, 2024 | 58,000.00 |
| Dec 31, 2024 | 58,000.00 |
| Sep 30, 2024 | 57,000.00 |
| Sep 30, 2024 | 57,000.00 |
| Jun 30, 2024 | 57,000.00 |
| Jun 30, 2024 | 57,000.00 |
| Mar 31, 2024 | 57,000.00 |
| Mar 31, 2024 | 57,000.00 |
| Dec 31, 2023 | 57,000.00 |
| Dec 31, 2023 | 57,000.00 |